Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages

  Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast; Endocrine therapy

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER STAGING; CHEMOPROPHYLAXIS; FEMALE SUBFERTILITY; HIGH RISK POPULATION; HUMAN; INTRADUCTAL CARCINOMA; MALE BREAST CANCER; OVULATION; REVIEW; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; FEMALE; MALE; TIME FACTOR;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; TAMOXIFEN; TIME FACTORS;

EID: 84903597977     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0092     Document Type: Review

References (73)

1. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D et al. 2012 Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncology 13 476-486. (doi:10.1016/S1470- 2045(12)70075-X)
2. Avigan J, Steinberg D, Vroman HE, Thompson MJ & Mosettig E 1960 Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. Journal of Biological Chemistry 235 3123-3126.
3. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC et al. 1983 Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2 450. (doi:10.1016/S0140-6736(83)90406-3) (Pubitemid 13043465)
4. Baumler E 1984 In Paul Ehrlich: Scientist for Life. New York, NY, USA: Holmes & Meier Pub.
5. Berry DA,Cronin KA,Plevritis SK, Fryback DG, Clarke L, ZelenM,Mandelblatt JS, Yakovlev AY, Habbema JD & Feuer EJ 2005 Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 353 1784-1792. (doi:10.1056/NEJMoa050518) (Pubitemid 41549890)
6. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R et al. 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer. New England Journal of Medicine 294 405-410. (doi:10.1056/NEJM197602192940801)
7. Cole MP, Jones CT & Todd ID 1971 A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. British Journal of Cancer 25 270-275. (doi:10.1038/bjc.1971.33)
8. Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, Falkson G & Arseneau J 1985 Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Annals of Internal Medicine 103 324-329. (doi:10.7326/0003-4819-103-3-324)
9. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S,McGale P, Pan HC, Taylor C, Wang YC et al. 2011 Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378 771-784. (doi:10.1016/S0140-6736(11)60993-8)
10. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X et al. 2013 Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381 805-816. (doi:10.1016/S0140-6736(12)61963-1)
11. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 71-85.
12. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467. (doi:10.1016/S0140-6736(97)11423-4)
13. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 1687-1717. (doi:10.1016/S0140-6736(05)66544-0)
14. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A et al. 2009 Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. Journal of the American Medical Association 302 774-780. (doi:10.1001/jama.2009.1204)
15. Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC & Falkson G 1990 Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. Journal of Clinical Oncology 8 599-607. (Pubitemid 20127242)
16. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL et al. 1975 L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. New England Journal of Medicine 292 117-122. (doi:10.1056/ NEJM197501162920301)
17. Fromson JM, Pearson S & Bramah S 1973a The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica 3 693-709. (doi:10.3109/00498257309151594)
18. Fromson JM, Pearson S & Bramah S 1973b The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica 3 711-714. (doi:10.3109/00498257309151595)
19. Gottardis MM & Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48 5183-5187.
20. Gottardis MM, Robinson SP, Satyaswaroop PG & Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 48 812-815. (Pubitemid 18061868)
21. Gottardis MM, Wagner RJ, Borden EC & Jordan VC 1989 Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Research 49 4765-4769. (Pubitemid 19213621)
22. Greaves P, Goonetilleke R, Nunn G, Topham J & Orton T 1993 Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Research 53 3919-3924. (Pubitemid 23267689)
23. Greenblatt RB, Barfield WE, Jungck EC & Ray AW 1961 Induction of ovulation with MRL/41. Preliminary report. Journal of the American Medical Association 178 101-104. (doi:10.1001/jama.1961.03040410001001)
24. Harper MJ &Walpole AL 1967 A new derivative of triphenylethylene: effect on implantation and mode of action in rats. Journal of Reproduction and Fertility 13 101-119. (doi:10.1530/jrf.0.0130101)
25. Henderson IC 1999 Early overviews of adjuvant tamoxifen therapy. In Tamoxifen for the Treatment and Prevention of Breast Cancer, pp 57-77. Ed VC Jordan. Melville, New York, NY, USA: PRR.
26. Hoagland M 1990 Towards the habbit of truth The Commonwealth Fund Book Program. New York, NY, USA: W. W. Norton & Company.
27. Hubay CA, Pearson OH, Marshall JS, Rhodes RS, DeBanne SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ et al. 1980 Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer 46 2805-2808. (doi:10.1002/1097-0142 (19801215)46:12C<2805::AID-CNCR2820461413>3.0.CO;2- H)
28. Ingle JN,AhmannDL,GreenSJ, EdmonsonJH,BiselHF,Kvols LK,NicholsWC, Creagan ET, Hahn RG, Rubin J et al. 1981 Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New England Journal of Medicine 304 16-21. (doi:10.1056/ NEJM198101013040104) (Pubitemid 11212892)
29. Jordan VC 1974 Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethyl benzanthracene (DMBA)-induced rat mammary carcinoma model. Journal of Steroid Biochemistry 5 354. (doi:10.1016/0022-4731(74)90388-4)
30. Jordan VC 1976a Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treatment Reports 60 1409-1419. (Pubitemid 8055853)
31. Jordan VC 1976b Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. European Journal of Cancer 12 419-424. (doi:10.1016/0014-2964(76)90030-X)
32. Jordan VC 1978 Use of the DMBA-induced ratmammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Reviews on Endocrine-Related Cancer (October supplement) 49-55.
33. Jordan VC 1983 Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Research and Treatment 3 S73-S86. (doi:10.1007/BF01855131)
34. Jordan VC 1984 Biochemical pharmacology of antiestrogen action. Pharmacological Reviews 36 245-276. (Pubitemid 15189558)
35. Jordan VC 1988 The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Breast Cancer Research and Treatment 11 197-209. (doi:10.1007/BF01807278)
36. Jordan VC 2001 Selective estrogen receptor modulation: a personal perspective. Cancer Research 61 5683-5687. (Pubitemid 32769076)
37. Jordan VC 2003 Tamoxifen: a most unlikely pioneering medicine. Nature Reviews. Drug Discovery 2 205-213. (doi:10.1038/nrd1031) (Pubitemid 37361665)
38. Jordan VC 2004 Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5 207-213. (doi:10.1016/S1535-6108(04)00059- 5) (Pubitemid 38402112)
39. Jordan VC 2006 Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology 147 (Suppl 1) S269-S276. (Pubitemid 43077285)
40. Jordan VC 2008 The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death? Journal of Clinical Oncology 26 3073-3082. (doi:10.1200/JCO.2008.17.5190)
41. Jordan VC 2013 Estrogen action, selective estrogen receptor modulators and women's health: progress and promise. London, UK: Imperial College Press.
42. Jordan VC & Allen KE 1980 Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBAinduced rat mammary carcinoma model. European Journal of Cancer 16 239-251. (doi:10.1016/0014-2964(80)90156-5) (Pubitemid 10166691)
43. Jordan VC & Koerner S 1975 Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. European Journal of Cancer 11 205-206. (doi:10.1016/0014-2964(75)90119-X)
44. Jordan VC & Prestwich G 1977 Binding of [3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Molecular and Cellular Endocrinology 8 179-188. (doi:10.1016/0303-7207(77)90090-9)
45. Jordan VC, Collins MM, Rowsby L & Prestwich G 1977 A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. Journal of Endocrinology 75 305-316. (doi:10.1677/joe.0.0750305)
46. Jordan VC, Dix CJ & Allen KE 1979 The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In Adjuvant Therapy II, pp 19-26. Eds SE Salmon & SE Jones. New York, NY, USA: Grune & Stratton.
47. Jordan VC, Zava DT, Eppenburger U, Kiser A, Sebek S, Dowdle E, Krozowski Z, Bennett RC, Funder J, Holdaway IM et al. 1983 Reliability of steroid hormone receptor assays: an international study. European Journal of Cancer & Clinical Oncology 19 357-363. (doi:10.1016/0277-5379(83)90133-5) (Pubitemid 13112480)
48. Klopper A & Hall M 1971 New synthetic agent for the induction of ovulation: preliminary trials in women. BMJ 1 152-154. (doi:10.1136/bmj.1.5741. 152)
49. Laughlin RC & Carey TF 1962 Cataracts in patients treated with triparanol. Journal of the American Medical Association 181 339-340. (doi:10.1001/jama.1962.03050300059020a)
50. Lerner LJ & Jordan VC 1990 Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Research 50 4177-4189. (Pubitemid 20225648)
51. Lerner LJ, Holthaus FJ Jr & Thompson CR 1958 A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 63 295-318. (doi:10.1210/endo-63-3-295)
52. LippmanME &BolanG 1975 Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256 592-593. (doi:10.1038/256592a0)
53. Ludwig Breast Cancer Study Group 1984 Randomised trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1 1256-1260.
54. Maximov PY, McDaniel RE & Jordan VC 2013 Tamoxifen: pioneering medicine in breast cancer Milestones in Drug Therapy. Basel, Switzerland: Springer.
55. Morgan LR Jr, Schein PS, Woolley PV, Hoth D, Macdonald J, Lippman M, Posey LE & Beazley RW 1976 Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treatment Reports 60 1437-1443. (Pubitemid 8055856)
56. Nolvadex Adjuvant Trial Organisation 1983 Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years. Lancet 1 257-261.
57. Obiorah I & Jordan VC 2013 Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause 20 372-382.
58. Peto R, Boreham J, Clarke M, Davies C & Beral V 2000 UK and USA breast cancer deaths down 25% in year at ages 20-69 years. Lancet 35 1822. (doi:10.1016/S0140-6736(00)02277-7)
59. Poirot M 2011 Four decades of discovery in breast cancer research and treatment-an interview with V. Craig Jordan. International Journal of Developmental Biology 55 703-712. (doi:10.1387/ijdb.113418mp)
60. Ribeiro G & Palmer MK 1983 Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. BMJ 286 827-830. (doi:10.1136/bmj.286.6368.827) (Pubitemid 13152396)
61. Ribeiro G & Swindell R 1985 The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma-7-yr results. European Journal of Cancer & Clinical Oncology 21 897-900. (doi:10.1016/0277-5379(85) 90104-X) (Pubitemid 15003369)
62. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M & Rasmussen BB 1985 Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1 16-19. (doi:10.1016/S0140-6736(85)90966-3)
63. Scottish Cancer Trials Office (MRC) 1987 Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Edinburgh. Lancet 2 171-175.
64. Segal SJ & Nelson WO 1958 An orally active compound with anti-fertility effects in rats. Proceedings of the Society for Experimental Biology and Medicine 98 431-436. (doi:10.3181/00379727-98-24068)
65. Sporn MB, Dunlop NM, Newton DL & Smith JM 1976 Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proceedings 35 1332-1338.
66. The aTTom Collaborative Group 2013 aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology 31 (Supplement 5).
67. Toft D & Gorski J 1966 A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. PNAS 55 1574-1581. (doi:10.1073/pnas.55.6.1574)
68. Toft D, Shyamala G & Gorski J 1967 A receptor molecule for estrogens: studies using a cell-free system. PNAS 57 1740-1743. (doi:10.1073/pnas.57.6. 1740)
69. Tormey DC & Jordan VC 1984 Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Research and Treatment 4 297-302. (doi:10.1007/BF01806042) (Pubitemid 15189799)
70. Tormey DC, Rasmussen P & Jordan VC 1987 Long-term adjuvant tamoxifen study: clinical update. Breast Cancer Research and Treatment 9 157-158. (doi:10.1007/BF01807370)
71. Ward HW 1973 Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. BMJ 1 13-14. (doi:10.1136/bmj.1.5844.13)
72. Wolf DM & Jordan VC 1993 A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results in Cancer Research 127 23-33.
73. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM& Jordan VC 2000 Antitumor action of physiological estradiol on tamoxifenstimulated breast tumors grown in athymic mice. Clinical Cancer Research 6 2028-2036. (Pubitemid 30305102)